MODULATING EFFECT OF CARVEDILOL ON ACTIVATION OF CYTOKINES IN PATIENTS WITH CHRONIC HEART FAILURE CAUSED BY ARTERIAL HYPERTENSION

Authors:

Abstract:

To assess the 6-month treatment with carvedilol, depending on the levels of proinflammatory cytokines (interleukin-1, interleukin-6 and tumor necrosis factor-α) in patients with arterial hypertension associated with chronic heart failure. The observation and treatment were conducted in 43 patients (mean age 51.3±3.2 years). The patients were divided in two groups. In patients of the 1st group with chronic heart failure of the II class according to New York Heart Association (n=22), the blood content of proinflammatory cytokines (p<0.05) reduced after treatment. In patients of the 2nd group with chronic heart failure of the III class according to New York Heart Association (n=21), the levels of cytokines also reduced after treatment (p<0.05). The change of cytokine level correlates with the improvement of global function of the left ventricle and arterial pressure. Thus, carvedilol is highly effective for correction of the activation of cytokines in patients with chronic heart failure caused by arterial hypertension.

Keywords:

chronic heart failure proinflammatory cytokines interleukin-1 interleukin-6 tumor necrosis factor-alpha

References:

1. Adamo L, Rocha-Resende C, Prabhu SD, Mann DL. Reappraising the role of inflammation in heart failure. Nat. Rev. Cardiol. 2020; 17: 269–285. 10.1038/s41569-019-0315-x.
2. Amin MN, Siddiqui SA, Ibrahim M, Hakim ML, Ahammed MS, Kabir A, et al. Inflammatory cytokines in the pathogenesis of cardiovascular disease and cancer. SAGE Open Med. 2020 Oct 20;8:2050312120965752. doi: 10.1177/2050312120965752.
3. de Freitas RA, Lima VV, Bomfim GF, Giachini FRC. Interleukin-10 in the vasculature: pathophysiological implications. Curr Vasc Pharmacol. 2022; 20: 230–243. doi: 10.2174/1570161120666211227143459.
4. dos Passos RR. Santos CV, Priviero F, Briones AM, Tostes RC, Clinton RW, et al. Immunomodulatory Activity of Cytokines in Hypertension: A Vascular Perspective. Hypertension; 2024; 81(7). Doi: 10.1161/HYPERTENSIONAHA.124.21712.
5. Haybar H, Bandar B, Torfi E, Mohebbi A, Saki N. Cytokines and their role in cardiovascular diseases, Cytokine, 2023; 169: 156261. https://doi.org/10.1016/j.cyto.2023.156261.
6. Hedayat M, Mahmoudi MJ, Taghvaei M, Nematipour E, Farhadi E, Esfahanian N, et al. Tumor Necrosis Factor-Alpha and Interleukin-6 Gene Polymorphisms in Iranian Patients with Ischemic Heart Failure. Avicenna J Med Biotechnol. 2018 Apr-Jun;10(2):105-109.
7. Li H, Chen C, Wang DW. Inflammatory Cytokines, Immune Cells, and Organ Interactions in Heart Failure. Front Physiol. 2021 Jul 1;12:695047. doi: 10.3389/fphys.2021.695047.
8. Loperena R, Beusecum JPV, Itani HA, Engel N, Laroumanie F, Xiao L, et al. Hypertension and increased endothelial mechanical stretch promote monocyte differentiation and activation: Roles of STAT3, interleukin 6 and hydrogen peroxide. Cardiovasc. Res. 2018;114:1547–1563. doi: 10.1093/cvr/cvy112
9. Schumacher SM, Naga Prasad SV. Tumor Necrosis Factor-α in Heart Failure: an Updated Review. Curr Cardiol Rep. 2018 Sep 26;20(11):117. doi: 10.1007/s11886-018-1067-7.
10. Silva LB, dos Santos Neto AP, Maia SMAS, dos Santos CG, Quidute IL, de Carvalho AAT, et al. The Role of TNF-α as a Proinflammatory Cytokine in Pathological Processes. The Open Dentistry Journal. 2019; 13: 332-338. Doi:10.2174/1874210601913010332.
11. Verma MK, Jaiswal A, Sharma P, Kumar P, Singh AN. Oxidative stress and biomarker of TNF-alpha, MDA and FRAP in hypertension. J Med Life. 2019;12:253–259. doi: 10.25122/jml-2019-0031.
12. Zhang H, Dhalla NS. The Role of Pro-Inflammatory Cytokines in the Pathogenesis of Cardiovascular Disease. Int J Mol Sci. 2024 Jan 16;25(2):1082. doi: 10.3390/ijms25021082.

Publication:

«World of Medicine and Biology» Vol. 21 No. 93 (2025) , с. 74-78
УДК 616.153.96:616.12-008.331.1

DOI:

https://doi.org/10.26724/2079-8334-2025-3-93-74-78